News from Wednesday, May 28, 2025
Articles
Rescuing Value-Based Healthcare Through Better Data
(5/28, Charles Hobson, Michael Pine, Christopher Tompkins, Health Affairs Forefront) comments “...A primary challenge in finally achieving high value healthcare in the US is discovering how to harness the comprehensive and nuanced data generated in the provision of care, which is available in each patient’s EHR, to support systemic care redesign to achieve better outcomes at lower cost. Adding that key ingredient could be transformative. The system currently used to extract data from EHRs in the US, ICD-10-CM, does not adequately capture clinical detail and nuance. Gaps, limitations, and errors in describing healthcare today lead directly to our inability to accurately measure both the outcomes resulting from the care provided and the cost of that care.” Full
Trump's 340B Request Could Further Convolute Existing Program Issues
(5/27, Gabrielle Wanneh, Inside Health Policy) reports “...[Richard Frank, director of the Center on Health Policy at the Brookings Institution,] says the president’s executive order does not propose any reform that would fix the 340B program’s core issues. ‘It’s this incredibly messy, complicated program right now and if you think the problem is basically that 340B is being used to buy all sorts of drugs for circumstances where it really isn’t aimed at helping safety net organizations survive, this doesn’t do anything about that,’ Frank told IDP.” Subscription Required
Could EU Collective Procurement Counter US Most Favored Nation Policy?
(5/28, Francesca Bruce, Pink Sheet) reports “...Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.” Subscription Required
Press Releases
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Spinal Muscular Atrophy
(5/27, ICER Press Release) “The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of apitegromab (Scholar Rock Holdings), nusinersen (Spinraza®, Biogen), onasemnogene abeparvovec-xioi (Zolgensma®, Novartis), and risdiplam (Evrysdi®, Genentech) for spinal muscular atrophy (SMA).” Full
Journals
Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021-March 2022)
Serena Vita, et al.
May 6, 2025, Microorganisms
Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic Review
Mingye Zhao, PhD; Taihang Shao, PhD; Yue Yin, PhD; et al
May 27, 2025, JAMA Network Open
A Bayesian Approach to the Survivor Average Causal Effect in Cluster-Randomized Crossover Trials
Dane Isenberg, et al.
May 27, 2025, arXiv
Comparative Effectiveness for Early-Stage NSCLC Without Lymph Node Involvement Based on Prospective Studies
Xue Yang, et al.
May 28, 2025, International Journal of Surgery
Real-World Data on Trastuzumab Emtansine (TDM1) Efficacy and Safety: Results of a Single-Centre Retrospective Study of HER2-Positive Metastatic Breast Cancer Patients
Anuj Gupta, et al.
May 28, 2025, Scientific Reports